Abcam, ab312868, Anti-DPD antibody [EPR26638-154] - BSA and Azide free (Detector)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal DPD antibody. Carrier free. Suitable for sELISA and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26638-154,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:sELISASee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Sandwich ELISA
The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DPD also known as dihydropyrimidine dehydrogenase is an enzyme important for the breakdown of pyrimidines particularly uracil and thymine. The DPD protein has an important role in the initial step of pyrimidine catabolism. It catalyzes the NADPH-dependent reduction of these pyrimidines to dihydrouracil and dihydrothymine. It consists of 1025 amino acids giving it a mass of approximately 111 kDa. DPD is expressed in various tissues with significant expression in the liver and to a lesser extent in peripheral blood lymphocytes.
Biological function summary
Dihydropyrimidine dehydrogenase impacts nucleotide metabolism which is significant for cellular replication and repair processes. DPD exists as part of a multi-enzyme complex that handles pyrimidine metabolism. It serves an important regulatory function by controlling the level of pyrimidines within cells. This regulation keeps the balance of free nucleotides which is critical for DNA synthesis and overall cellular homeostasis.
Pathways
DPD holds an important position in pyrimidine metabolism pathways and the drug metabolism pathway specifically influencing fluoropyrimidine-based chemotherapeutic agents. Within the pyrimidine metabolic pathway DPD links to other enzymes that further breakdown pyrimidines into more basic compounds. In drug metabolism DPD plays a vital role by metabolizing drugs like 5-fluorouracil. Its activity affects how individuals process these medications linking it to enzymes like thymidylate synthase that share pathways in cancer treatment drug action.
DPD deficiency relates to a genetic disorder that causes an excessive build-up of uracil and thymine leading to developmental disorders and neurological problems. Additionally abnormalities in DPD activity influence the efficacy and toxicity of fluorouracil chemotherapy in cancer treatments. DPD enzymatic activity when not properly regulated can lead to severe toxic reactions especially in relation to therapies reliant on enzymes such as thymidylate synthase emphasizing the critical interplay between these proteins in the management of fluoropyrimidine drug treatments.